Dow Down1.29% Nasdaq Down3.25%

Opko Health, Inc. (OPK)

-NYSE
8.26 Down 0.18(2.13%) Feb 5, 4:01PM EST
|After Hours : 8.26 0.00 (0.00%) Feb 5, 4:57PM EST
ProfileGet Profile for:
Opko Health, Inc.
4400 Biscayne Boulevard
Miami, FL 33137
United States - Map
Phone: 305-575-4100
Website: http://www.opko.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:674

Business Summary 

OPKO Health, Inc., a biopharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies in the United States and internationally. It operates through two segments, Pharmaceuticals and Diagnostics. The company develops various solutions to diagnose, treat, and prevent various conditions, including point-of-care tests, molecular diagnostics tests, laboratory developed tests, and proprietary pharmaceuticals and vaccines. Its products include 4Kscore test that measures the blood plasma levels of four different prostate-derived kallikrein proteins. The company’s lead product candidates comprise Rayaldee to treat secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease and vitamin D insufficiency; and Alpharen to treat hyperphosphatemia in stage 5 patients on chronic hemodialysis. It is also developing CTP, hGH-CTP for the treatment of growth hormone deficiency; Factor VII-CTP for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX; Inspiromatic, a powder inhaler for use in the therapy for asthma, chronic obstructive pulmonary disease, cystic fibrosis, and other respiratory diseases; and rolapitant for the prevention of chemotherapy induced nausea and vomiting, as well as focuses on the development of a long-acting oxyntomdulinGLP-1/glucagon dual receptor agonist. In addition, the company is developing Claros1 immunoassay instrument system that provides rapid blood test results and enables complex tests to be run in point-of-care settings; drugs for the treatment cancer, heart disease, metabolic disorders, and various genetic anomalies; and has various therapeutic agents in clinical development for the treatment of respiratory disorders. Further, it operates a full-service medical laboratory specializing in urologic pathology. OPKO Health, Inc. is based in Miami, Florida.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Opko Health, Inc.

Corporate Governance 
Opko Health, Inc.’s ISS Governance QuickScore as of Feb 1, 2016 is 9. The pillar scores are Audit: 10; Board: 10; Shareholder Rights: 3; Compensation: 8.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Dr. Phillip Frost M.D., Ph.D., 80
Chairman and Chief Exec. Officer
790.00K205.00K
Dr. Jane H. Hsiao Ph.D., MBA., 69
Vice Chairman and Chief Technical Officer
560.00K1.22M
Mr. Adam Logal , 38
Chief Financial Officer, Chief Accounting Officer, Sr. VP and Treasurer
310.00K0.00
Mr. Steven D. Rubin J.D., 56
Exec. VP of Admin. and Director
490.00K2.00M
Ms. Kate Inman Esq.,
Deputy Gen. Counsel and Sec.
N/AN/A
Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders